不同劑量SEC與SMC之抗氧化作用-糖尿病動物模式之研究

The antioxidant activity of s-ethyl cysteine and s-methyl cysteine at various doses-Diabetic animal model

蔣佩芳(Pei-Fang Chiang)

指導教授 ： 殷梅津

中山醫學大學/健康管理學院/營養學研究所/碩士(2007年)

https://doi.org/10.6834/CSMU.2007.00038

摘要

糖尿病是台灣地區重要的慢性病之ㄧ，且其併發症的複雜使得該疾病難以控制。本研究是在探討來自大蒜的水溶性含硫化合物S-methyl cysteine（SMC）及S-ethyl cysteine（SEC）對於糖尿病老鼠的保護作用。採用Balb/c雄鼠，經尾靜脈注射Streptozotocin（STZ；200mg/kg）誘發糖尿病，確認糖尿病誘發成功後，再於Balb/c老鼠飲水中分別加入2 g/L（高劑量，H）、1 g/L（中劑量，M）和0.5 g/L（低劑量，L）的SMC及2 g/L（高劑量）、1 g/L（中劑量）的SEC，其組別分別為（1）Control（2）DM-Water（3）DM-SMCH（4）DM-SMCM（5）DM-SMCL（6）DM-SECH（7）DM-SECM，期間採自由飲食、飲水的方式。經餵食四週後犧牲。實驗分析血漿中的葡萄糖、胰島素、麩胱苷肽過氧化酶、纖維網狀蛋白、肌酸酐、C-反應蛋白、血尿素氮等含量變化、蛋白激酶C以及轉化生長因子-β1的活性及脂質過氧化程度。結果顯示，飲用SMC與SEC的糖尿病小白鼠不論高中低劑量皆會使血糖顯著性的下降（p＜0.05），飲用SMC之特殊飲水可延緩糖尿病所引起的纖維網狀蛋白。抗氧化方面，麩胱苷肽過氧化酶活性有顯著增加（p＜0.05）。在腎臟保護方面，飲用高中低劑量之SMC與SEC均顯著降低其血中尿素氮（p＜0.05）；而轉化生長因子-β1則以中低劑量的SMC下降較顯著（p＜0.05）。由上述結果顯示出，飲水中添加大蒜的水溶性含硫化合物S-methyl cysteine及S-ethyl cysteine皆有助於改善糖尿病併發症的發生。

關鍵字

糖尿病 ； 小鼠 ； 大蒜含硫化合物 ； Streptozotocin

並列摘要

Diabetes is one of the major chronic diseases in Taiwan. It is hardly controlled because of its complications. This study was to examine the protection from S-methyl cysteine (SMC) and S-ethyl cysteine (SEC), two sulfur compounds derived from garlic, against diabetic deterioration in streptozotocin-induced diabetic mice. These agents were added at 2 g/L (high dose, H), 1 g/L (medium dose, M), and 0.5 g/L(low dose, L) in drinking water for 4 weeks supplementation. Blood levels of glucose, insulin, glutathione peroxidase, fibronectin, caretinine, blood urea nitrogen, c-reactive protein, transforming growth factor-beta and lipid oxidation were analyzed. Results showed that the intake of both agents could significantly decrease blood glucose and BUN (p<0.05), and increase GPX activity (p<0.05). The intake of SMC could significantly suppress fibronectin level and TGF-β (p<0.05). These results indicated that the intake of SEC and/or SMC could alleviate diabetic deterioration.

並列關鍵字

Diabetes mellitus ； mice ； S-methyl cysteine ； S-ethyl cysteine ； Streptozotocin

參考文獻

3. 陳建銘、陳建良: 糖尿病腎病變. 腎臟與透析 2005;17:117-122.

4. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-794.

6. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408.

7. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP: Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999;42:222-232.

8. Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D: Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med Res Rev 1999;19:3-23.